|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400084007 |
|
最近更新日期: Date of Last Refreshed on: |
2024-05-09 08:50:40 |
|
注册时间: Date of Registration: |
2024-05-09 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
膳食干预围绝经期综合征患者DNAmAge调查研究 |
|
Public title: |
A Study on DNAmAge in Patients with Perimenopausal Syndrome after Dietary Intervention |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
膳食干预围绝经期综合征患者DNAmAge调查研究 |
|
Scientific title: |
A Study on DNAmAge in Patients with Perimenopausal Syndrome after Dietary Intervention |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
钟晓玲 |
研究负责人: |
杨琳 |
|
Applicant: |
Zhong Xiaoling |
Study leader: |
Yang Lin |
|
申请注册联系人电话: Applicant telephone: |
+86 188 0138 9656 |
研究负责人电话:
Study leader's |
+86 139 8488 5851 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18801389656@163.com |
研究负责人电子邮件: Study leader's E-mail: |
1103965005@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
贵州医科大学 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
贵州省贵州医科大学 |
研究负责人通讯地址: |
贵州省贵州医科大学附属医院急诊妇产科 |
|
Applicant address: |
Guizhou Medical University, Guizhou Province |
Study leader's address: |
Department of Emergency Obstetrics and Gynecology, Affiliated Hospital of Guizhou Medical University, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
贵州医科大学 |
||
|
Applicant's institution: |
Guizhou Medical University |
||
|
研究负责人所在单位: |
贵州医科大学附属医院 |
||
|
Affiliation of the Leader: |
The Affiliated Hospital of Guizhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021伦审第(675)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
贵州医科大学附属医院医学科学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Science Ethics Committee of the Affiliated Hospital of Guizhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-10-12 00:00:00 | ||
|
伦理委员会联系人: |
刘文 |
||
|
Contact Name of the ethic committee: |
Liu Wen |
||
|
伦理委员会联系地址: |
贵州省贵阳市云岩区贵医街28号 |
||
|
Contact Address of the ethic committee: |
No. 28, Guiyi Street, Yunyan District, Guiyang City, Guizhou Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 851 8681 4581 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
贵州医科大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Affiliated Hospital of Guizhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省贵阳市北京路4号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 4 Beijing Road, Guiyang City, Guizhou Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
贵州省卫生健康委科学技术基金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Science and Technology Fund Project of Guizhou Provincial Health Commission |
||||||||||||||||||||||
|
研究疾病: |
围绝经期综合征 |
||||||||||||||||||||||
|
Target disease: |
Perimenopausal syndrome |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
绝经过渡期是每个女性都面临的一个重要时期,约90%以上的妇女将出现与绝经相关的症状,虽然目前激素替代仍然是最为有效的治疗方法,但由于其使用的禁忌症和本身的副作用,其在临床治疗中仍存在一定的局限性。现有研究表明,食物中的功能活性成分以及不同的膳食模式对围绝经期妇女的代谢及相关症状有一定的改善作用。此外,DNA 甲基化是一种新兴的生物老化估计器,是生物衰老的标志之一,被认为是预测认知能力下降的生物标志物。我们前期研究提示DNAmAge可能与围绝经期综合征存在一定的联系,同时膳食干预对围绝经期综合征患者的影响,能够通过DNAmAge体现出来。本项目通过仅使用膳食干预的方法,对干预前后围绝经期综合征患者的症状和DNA甲基化指标进行比较分析,研究围绝经期综合征治疗与DNA甲基化的相关性,为进一步探索围绝经期综合征的治疗方式提供理论基础。通过DNAmAge作为膳食干预的效果指标,缓解近期围绝经期综合征患者的症状和减少远期围绝经期综合征患者的并发症。 |
||||||||||||||||||||||
|
Objectives of Study: |
Menopause transition is an important period that every woman faces, more than 90% of women will have menopause-related symptoms, although hormone replacement is still the most effective treatment, but due to its contraindications to use and its own side effects, it still has certain limitations in clinical treatment. Existing studies have shown that functional active ingredients in food and different dietary patterns have a certain effect on metabolism and related symptoms in perimenopausal women. In addition, DNA methylation is an emerging bioaging estimator that is one of the hallmarks of biological aging and is considered a biomarker for predicting cognitive decline. Our previous research suggests that DNAmAge may be associated with perimenopausal syndrome, and the impact of dietary interventions on patients with perimenopausal syndrome can be seen through DNAmAge. This project compares and analyzes the symptoms and DNA methylation indexes of perimenopausal syndrome patients before and after the intervention by using only dietary intervention, and studies the correlation between perimenopausal syndrome treatment and DNA methylation, which provides a theoretical basis for further exploring the treatment of perimenopausal syndrome. DNAmAge was used as an indicator of the effect of dietary intervention to alleviate symptoms in patients with recent perimenopausal syndrome and reduce complications in patients with long-term perimenopausal syndrome. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄 45-55 岁;有围绝经期综合征的临床症状、体征和诊断;以前未接受过激素补充治疗。 |
||||||||||||||||||||||
|
Inclusion criteria |
age 45-55; clinical symptoms, signs, diagnosis of perimenopausal syndrome; no previous hormone supplementation therapy. |
||||||||||||||||||||||
|
排除标准: |
曾用过激素替代、中医中药,绝经一年后的患者;高血压、糖尿病、肿瘤等严重妇科疾病的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients who have used hormone replacement, traditional Chinese medicine and one year after menopause; patients with serious gynecological diseases such as hypertension, diabetes and tumors. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2024-01-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-04-01 00:00:00 至 To 2022-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
not |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
ResMan临床试验公共管理平台 http://www.medresman.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
http://www.medresman.org.cn/pub/cn/proj/search.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |